NASDAQ: CGEN
Compugen Ltd Stock Forecast, Predictions & Price Target

Analyst price target for CGEN

Based on 1 analyst offering 12 month price targets for Compugen Ltd

Min Forecast
$4.00+142.42%
Avg Forecast
$4.00+142.42%
Max Forecast
$4.00+142.42%

Should I buy or sell CGEN stock?

Based on 1 analyst offering ratings for Compugen Ltd.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CGEN's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates CGEN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their CGEN stock forecasts and price targets.

CGEN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-07

1 of 1

Forecast return on equity

Is CGEN forecast to generate an efficient return?

Company
-79.82%
Industry
269.17%
Market
236.85%
CGEN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CGEN forecast to generate an efficient return on assets?

Company
-35.75%
Industry
113.96%
CGEN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CGEN earnings per share forecast

What is CGEN's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.22
Avg 2 year Forecast
-$0.17
Avg 3 year Forecast
-$0.40

CGEN revenue forecast

What is CGEN's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$18.3M+164.88%
Avg 2 year Forecast
$29.0M+320.03%
Avg 3 year Forecast
$34.7M+402.88%
CGEN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CGEN revenue growth forecast

How is CGEN forecast to perform vs Biotechnology companies and vs the US market?

Company
72.87%
Industry
117.62%
Market
23.19%
CGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CGEN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CGEN$1.65$4.00+142.42%Buy
TLSA$1.39N/AN/A
ADAG$3.25$8.33+156.40%Strong Buy
IPSC$1.75$3.00+71.43%Buy
ABOS$2.51$7.50+198.80%Strong Buy

Compugen Stock Forecast FAQ

Is Compugen Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CGEN) stock is to Buy CGEN stock.

Out of 1 analyst, 0 (0%) are recommending CGEN as a Strong Buy, 1 (100%) are recommending CGEN as a Buy, 0 (0%) are recommending CGEN as a Hold, 0 (0%) are recommending CGEN as a Sell, and 0 (0%) are recommending CGEN as a Strong Sell.

If you're new to stock investing, here's how to buy Compugen stock.

What is CGEN's earnings growth forecast for 2026-2028?

(NASDAQ: CGEN) Compugen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 61.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.85%.

Compugen's earnings in 2026 is -$27,619,000.On average, 7 Wall Street analysts forecast CGEN's earnings for 2026 to be -$20,419,469, with the lowest CGEN earnings forecast at -$32,083,728, and the highest CGEN earnings forecast at -$982,155. On average, 7 Wall Street analysts forecast CGEN's earnings for 2027 to be -$15,649,002, with the lowest CGEN earnings forecast at -$33,000,406, and the highest CGEN earnings forecast at $7,857,239.

In 2028, CGEN is forecast to generate -$37,209,641 in earnings, with the lowest earnings forecast at -$41,250,507 and the highest earnings forecast at -$32,411,113.

What is CGEN's revenue growth forecast for 2026-2028?

(NASDAQ: CGEN) Compugen's forecast annual revenue growth rate of 72.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.62%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.19%.

Compugen's revenue in 2026 is $6,903,000.On average, 7 Wall Street analysts forecast CGEN's revenue for 2026 to be $1,710,352,661, with the lowest CGEN revenue forecast at $0, and the highest CGEN revenue forecast at $4,874,668,776. On average, 7 Wall Street analysts forecast CGEN's revenue for 2027 to be $2,712,150,692, with the lowest CGEN revenue forecast at $0, and the highest CGEN revenue forecast at $6,593,439,908.

In 2028, CGEN is forecast to generate $3,247,097,745 in revenue, with the lowest revenue forecast at $45,833,897 and the highest revenue forecast at $6,347,901,175.

What is CGEN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CGEN) forecast ROA is -35.75%, which is lower than the forecast US Biotechnology industry average of 113.96%.

What is CGEN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CGEN price target, the average CGEN price target is $4.00, with the highest CGEN stock price forecast at $4.00 and the lowest CGEN stock price forecast at $4.00.

The Wall Street analyst predicted that Compugen's share price could reach $4.00 by Jan 7, 2027. The average Compugen stock price prediction forecasts a potential upside of 142.42% from the current CGEN share price of $1.65.

What is CGEN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CGEN) Compugen's current Earnings Per Share (EPS) is -$0.30. On average, analysts forecast that CGEN's EPS will be -$0.22 for 2026, with the lowest EPS forecast at -$0.34, and the highest EPS forecast at -$0.01. On average, analysts forecast that CGEN's EPS will be -$0.17 for 2027, with the lowest EPS forecast at -$0.35, and the highest EPS forecast at $0.08. In 2028, CGEN's EPS is forecast to hit -$0.40 (min: -$0.44, max: -$0.35).

What is CGEN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CGEN) forecast ROE is -79.82%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.